Is Eli Lilly and Company Stock (LLY) Overbought or Oversold?
RSI analysis computed from LLY's daily closing prices · Data through July 2, 2026
As of July 2, 2026, LLY’s 14-day RSI is 72.2, above the conventional overbought threshold of 70 — the stock has risen quickly relative to its recent trading range.
RSI-14 Scale
LLY reads 72.2 on the 0–100 scale.
The Supporting Picture
vs 50-Day MA
+18.6%
MA: $1012.91
vs 200-Day MA
+32.8%
MA: $904.69
From 52-Wk High
-1.4%
High: $1229.01
Volume vs 20-Day Avg
-15%
Avg: 2.0M shares
The 50-day average is currently above the 200-day average, which technicians read as a longer-term uptrend backdrop for the RSI reading above.
What's Behind the Reading
July 6, 2026Eli Lilly and Company's stock is currently in an overbought condition, with an RSI-14 of 72.17 and its price trading 19.1% above its 50-day moving average, just 1.42% shy of its 52-week high. This strong performance is largely attributable to exceptional first-quarter 2026 earnings, where the company reported an EPS of $8.55, significantly exceeding analyst expectations of $6.85. Quarterly revenue also surged by 55.5% year-over-year to $19.80 billion, surpassing analyst estimates. Recent positive developments, such as the company's inclusion in Medicare coverage for GLP-1 medications, are expected to drive substantial patient growth in obesity and diabetes treatments. Analysts also highlight Eli Lilly's dominant market share in the U.S. weight-loss drug sector and upcoming oral formulations as key growth catalysts.
Recent Overbought / Oversold Episodes
How LLY behaved the last few times RSI left the neutral band — including its return over the 5 trading days after each episode ended.
| Episode | Period | Next 5 Days |
|---|---|---|
| overbought | June 29, 2026 – July 2, 2026 | Ongoing |
| oversold | March 27, 2026 | +35.7% |
| overbought | November 3, 2025 – November 28, 2025 | -6.1% |
| overbought | October 3, 2025 – October 9, 2025 | -4.2% |
Past behavior does not predict future results — small sample sizes especially.
Frequently Asked Questions
Is Eli Lilly and Company (LLY) overbought right now?
What is RSI (Relative Strength Index)?
Is an overbought stock a sell signal?
How often is this page updated?
Where does this data come from?
Methodology
The verdict on this page is mechanical: we compute the 14-day Relative Strength Index with Wilder’s smoothing from LLY’s daily closing prices, and apply the conventional thresholds — above 70 is overbought, below 30 is oversold. Moving averages, the 52-week range, and volume comparisons come from the same price history.
Indicators are recomputed after every market close. The AI commentary adds context from current news via grounded search, but never changes the computed verdict. Note: closes are as-traded; a stock split would distort readings for a few weeks until the window rolls past it.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on LLY
Eli Lilly and Company Overview
Price, chart, analysis & financials
LLY: Why Is It Moving?
Updated daily
LLY: Price Prediction
Updated daily
LLY: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers